As many of your will know, EAN works closely with our colleagues at the European Federation of Neurological Association [EFNA] – who so actively work to promote the patient perspective in all healthcare policy and provision in Europe.
EFNA… Continue Reading 
The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019 according to a new study within the EAN-led Cost of Illness in Neurology in Europe (COIN-Eu) initiative.
Latest Posts
-
As many of your will know, EAN works closely with our colleagues at the European Federation of Neurological Association [EFNA] – who so actively work to promote the patient perspective in all healthcare policy and provision in Europe.
EFNA… Continue Reading
-
The INSTITUTE OF NEUROLOGICAL SPECIALITIES (IENSA) announce the call for the Dr. Pedro Albert Grant 2016, intended for all medicine and psychology graduates who wish to present a clinical research project in any area of neuroscience. More information on www.iensa.es.… Continue Reading
-
The European Brain Council (EBC) is carrying out a new Study for 2015-2017 on the “Value of Treatment: Bridging the Early Diagnosis and Treatment Gap for Brain Disorders”.
-
The Commission has just published a roadmap concerning policy areas of interest to EAN. The roadmaps concern the following policy areas: Food Safety Public Health To consult all the existing roadmaps please refer to the following website:
http://ec.europa.eu/smart-regulation/roadmaps/index_en.htm For further… Continue Reading -
Brain health in an ageing population – One in three individuals over the age of 80 suffers from at least one neurological disease – Raising awareness for an underestimated problem – More prevention can mitigate human suffering and economic consequences… Continue Reading -
Babinski is the association of neurologists in training in Flanders – the Dutch-speaking part of Belgium. Residents from all 4 medical universities are included: Ghent, Leuven, Antwerp and Brussels. Babinski was founded in the summer of 2015.
-
We are delighted to inform that our media partner touchNEUROLOGY has produced the following discussions during the EAN congress 2016 in Copenhagen: EAN 2016 Peter Goadsby Interview on the rationale for using CGRP antibodies in the treatment of migraine… Continue Reading
-
Breaking newsFeatured SliderBreaking news: Genetic movement disorders – a powerful new online resource
The International Parkinson Disease and Movement Disorders Society (MDS) Task Force on Genetic Nomenclature in Movement Disorders developed an online database providing a comprehensive overview of movement disorders phenotypes linked to causative gene mutations. MDSGene was just revealed at the… Continue Reading -
During the second EAN congress in Copenhagen, the current board of the EAN has been reappointed with a very strong majority and as the first president elect of the newly structured board, Franz Fazekas from Graz, Austria was elected. He will be the next president in two years from now. The board and myself thank the delegates for this confidence shown to us. We interpret this as a strong mandate to follow and expand the tracks that we have already started to follow. This is to briefly outline two of these avenues. Meanwhile, the major goals for our Society are outlined in the strategic plan. -
Are you looking for an exciting opportunity to develop your professional standing, leadership skills, and to make new neuro-friends from across Europe?
Members of our standing committees kindly serve EAN for a 4-year term. Therefore, we need to renew part… Continue Reading -
Finland, officially the Republic of Finland (in Finnish: Suomi), is the northernmost and the most sparsely populated country in the European Union. By size, it is the fifth-largest country in Western Europe with its 338,440 km² of land, and with a population of 5.5 million (16 persons/km²). Politically, Finland has been a parliamentary democracy since its independence 1917, after having been a grand duchy of Russian empire for 108 years and prior to that a part of Sweden for 600 years. -
Paper of the MonthTop ArticlesPaper of the month: Aspirin efficacy in secondary prevention of early ischaemic cerebrovascular events
For July 2016 we have selected: Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomized trials. Rothwell PM, Algra A, Chen Z, Diener H-C, Norrving B, Mehta Z. Lancet Neurol 2016 May 18. doi: 10.1016/S0140-6736(16)30468-8. Whereas there is robust evidence encouraging the use of aspirin for long-term secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke, data supporting aspirin treatment to reduce early recurrence of ischæmic events is weak. Moreover, even less information is available concerning the early aspirin effects on risk or severity recurrence after minor strokes. -
Interviews
Interview with Prof. Walter Paulus, Chair of the International Federation of Clinical Neurophysiology
DV (David B. Vodušek): Can you please illustrate the European Chapter of IFCN to the readers of the EAN pages? What is the formal relationship of the European chapter to IFCN? WP (Walter Paulus): The European Chapter (EC-IFCN) is one of four chapters of the International Federation of Clinical Neurophysiology (IFCN), with the others being North America, South America and Oceania. -
InterviewsEur J NeurolFeatured SliderVideo interview with Prof. A. Schapira editor-in-chief of the European Journal of Neurology
By Elena Moro Video interview with Prof. A. Schapira editor-in-chief of the European Journal of Neurology was last modified: August 1st, 2016 by Editor… Continue Reading -
Length-dependent axonal degeneration typically occurs in axonal neuropathies. This “dying back” phenomenon occurs in the largest and longest axons. Because in these axons the demand for maintenance is highest and delivery of metabolites most challenging, impairment of metabolic processes essential… Continue Reading